Not Logged In

OraSure Technologies, Inc. develops, manufactures, and markets oral fluid diagnostic products and specimen collection devices using its proprietary oral fluid technologies. Its diagnostic products include tests that are performed on a rapid basis at the point of care; and tests, which are processed in a laboratory. The principal products comprise OraQuick ADVANCE HIV-1/2, OraQuick In-Home HIV Test, OraQuick HCV, OraSure QuickFlu rapid flu A&B test, OraSure, Oragene DX, Oragene DNA, Oragene DISCOVER, Oragene RNA, ORAcollect, OMNIgene DISCOVER, Performagene LIVESTOCK and Oragene ANIMAL, Intercept, MICRO-PLATE DOA Assays, Homogeneous DOA Assays, and professional and over-the-counter Cryosurgical Systems. In addition, the company, through its subsidiary, DNA Genotek Inc., manufactures and sell kits used to collect, stabilize, and store samples of genetic material for molecular testing in the academic research, clinical genetic testing, pharmacogenomics, personalized medicine, and animal and livestock genetics markets. Its OraGene DNA sample collection kit provides an all-in-one system for the collection, stabilization, and transportation of DNA from human saliva. Further, the company offers medical devices used for the removal of benign skin lesions by cryosurgery or freezing. Additionally, it sells certain immunoassay tests and reagents for insurance risk assessment, substance abuse testing, and forensic toxicology applications; an oral fluid Western blot HIV-1 confirmatory test for confirming positive HIV-1 test; and the FDA 510(k) cleared Q.E.D. rapid point-of-care saliva alcohol test. The company sells its products to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities in the United States and internationally. OraSure Technologies, Inc. was founded in 1979 and is based in Bethlehem, Pennsylvania.